Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

被引：4

作者：

Wang, Jianxiang ^{[1
]}

Jiang, Bin ^{[2
]}

Li, Jian ^{[3
]}

Liu, Ligen ^{[4
]}

Du, Xin ^{[5
]}

Jiang, Hao ^{[6
]}

Hu, Jianda ^{[7
]}

Yuan, Menghe

Sakatani, Taishi ^{[8
]}

Kadokura, Takeshi ^{[9
]}

Takeuchi, Masato ^{[9
]}

Izuka, Shunsuke ^{[9
]}

Girshova, Larisa ^{[10
]}

Tan, Jerome ^{[11
]}

Bondarenko, Sergey N. ^{[12
]}

Wong, Lily L. L. ^{[13
]}

Khuhapinant, Archrob ^{[14
]}

Martynova, Elena ^{[15
]}

Hasabou, Nahla ^{[16
]}

Tiu, Ramon V. ^{[16
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China

[2] Peking Univ Int Hosp, Dept Hematol, Beijing, Peoples R China

[3] Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

[4] Shanghai Tongren Hosp, Dept Hematol, Shanghai, Peoples R China

[5] Guangdong Prov Peoples Hosp, Dept Hematol, Guangzhou, Peoples R China

[6] Peking Univ Peoples Hosp, Dept Hematol, Beijing, Peoples R China

[7] Fujian Med Univ Union Hosp, Fujian Inst Hematol, Fuzhou, Fujian, Peoples R China

[8] Astellas Pharma Inc, Beijing, Peoples R China

[9] Astellas Pharma Inc, Tokyo, Japan

[10] Almazov Natl Med Res Ctr, St Petersburg, Russia

[11] Univ Malaysia Sarawak, Fac Med & Hlth Sci, Dept Med, Dept Hematol,Ampang Hosp Selangor, Sarawak, Malaysia

[12] State Med Univ, Clin Res Inst Pediat Hematol & Transplantat Name, St Petersburg, Russia

[13] Queen Elizabeth Hosp, Dept Hematol, Kota Kinabalu, Sabah, Malaysia

[14] Mahidol Univ, Fac Med Siriraj Hosp, Div Hematol, Dept Med, Bangkok, Thailand

[15] Skolkovo Inst Sci & Technol, Moscow, Russia

[16] Astellas Pharma Inc, Northbrook, IL USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145436

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

695

引用

页数：4

共 50 条

[1] Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia
Wang, Jianxiang
Jiang, Bin
Li, Jian
Liu, Ligen
Du, Xin
Jiang, Hao
Hu, Jianda
Yuan, Menghe
Sakatani, Taishi
Kadokura, Takeshi
Takeuchi, Masato
Kosako, Masanori
Ma, Xiao
Girshova, Larisa
Tan, Jerome
Bondarenko, Sergey
Lee, Lily Wong Lee
Khuhapinant, Archrob
Martynova, Elena
Hasabou, Nahla
LEUKEMIA, 2024, 38 (11) : 2410 - 2418
[2] Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
Hosono, Naoko
Yokoyama, Hisayuki
Aotsuka, Nobuyuki
Ando, Kiyoshi
Iida, Hiroatsu
Ishikawa, Takayuki
Usuki, Kensuke
Onozawa, Masahiro
Kizaki, Masahiro
Kubo, Kohmei
Kuroda, Junya
Kobayashi, Yukio
Shimizu, Takayuki
Chiba, Shigeru
Nara, Miho
Hata, Tomoko
Hidaka, Michihiro
Fujiwara, Shin-Ichiro
Maeda, Yoshinobu
Morita, Yasuyoshi
Kusano, Mikiko
Lu, Qiaoyang
Miyawaki, Shuichi
Berrak, Erhan
Hasabou, Nahla
Naoe, Tomoki
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (11) : 2131 - 2141
[3] Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
Naoko Hosono
Hisayuki Yokoyama
Nobuyuki Aotsuka
Kiyoshi Ando
Hiroatsu Iida
Takayuki Ishikawa
Kensuke Usuki
Masahiro Onozawa
Masahiro Kizaki
Kohmei Kubo
Junya Kuroda
Yukio Kobayashi
Takayuki Shimizu
Shigeru Chiba
Miho Nara
Tomoko Hata
Michihiro Hidaka
Shin-Ichiro Fujiwara
Yoshinobu Maeda
Yasuyoshi Morita
Mikiko Kusano
Qiaoyang Lu
Shuichi Miyawaki
Erhan Berrak
Nahla Hasabou
Tomoki Naoe
International Journal of Clinical Oncology, 2021, 26 : 2131 - 2141
[4] Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
McMahon, Christine M.
Perl, Alexander E.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 841 - 849
[5] Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Daver, Naval
Perl, Alexander E.
Maly, Joseph
Levis, Mark
Ritchie, Ellen
Litzow, Mark
McCloskey, James
Smith, Catherine C.
Schiller, Gary
Bradley, Terrence
Tiu, Ramon, V
Naqvi, Kiran
Dail, Monique
Brackman, Deanna
Siddani, Satya
Wang, Jing
Chyla, Brenda
Lee, Paul
Altman, Jessica K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4048 - +
[6] Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
McMahon, Christine M.
Canaani, Jonathan
Rea, Bryan
Sargent, Rachel L.
Qualtieri, Julianne N.
Watt, Christopher D.
Morrissette, Jennifer J. D.
Carroll, Martin
Perl, Alexander E.
BLOOD ADVANCES, 2019, 3 (10) : 1581 - 1585
[7] An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.
Perl, Alexander E.
Cortes, Jorge E.
Strickland, Stephen Anthony
Ritchie, Ellen K.
Neubauer, Andreas
Martinelli, Giovanni
Naoe, Tomoki
Pigneux, Arnaud
Rousselot, Philippe H.
Rollig, Christoph
Baer, Maria R.
Larson, Richard A.
James, Angela Joubert
Chen, Caroline
Shu, Lei
Hasabou, Nahla
Bahceci, Erkut
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8] Outcomes in Patients with FLT3-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
Perl, Alexander E.
Larson, Richard A.
Podoltsev, Nikolai A.
Strickland, Stephen
Wang, Eunice S.
Atallah, Ehab
Schiller, GaryJ.
Martinelli, Giovanni
Neubauer, Andreas
Sierra, Jorge
Montesinos, Pau
Recher, Christian
Yoon, Sung-Soo
Maeda, Yoshinobu
Hosono, Naoko
Onozawa, Masahiro
Kato, Takayasu
Kim, Hee-Je
Hasabou, Nahla
Nuthethi, Rishita
Tiu, Ramon
Levis, Mark J.
TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (04):
[9] Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
Perl, A. E.
Martinelli, G.
Cortes, J. E.
Neubauer, A.
Berman, E.
Paolini, S.
Montesinos, P.
Baer, M. R.
Larson, R. A.
Ustun, C.
Fabbiano, F.
Erba, H. P.
Di Stasi, A.
Stuart, R.
Olin, R.
Kasner, M.
Ciceri, F.
Chou, W-C
Podoltsev, N.
Recher, C.
Yokoyama, H.
Hosono, N.
Yoon, S-S
Lee, J-H
Pardee, T.
Fathi, A. T.
Liu, C.
Hasabou, N.
Liu, X.
Bahceci, E.
Levis, M. J.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18): : 1728 - 1740
[10] Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia
Connie Kang
Hannah A. Blair
Targeted Oncology, 2020, 15 : 681 - 689

← 1 2 3 4 5 →